In a major leap for male contraception, biotech startup Contraline has announced that its injectable male contraceptive, ADAM, remains effective two years into its first human clinical trial. The milestone positions ADAM as a potentially game-changing alternative to condoms and vasectomies.
Unlike hormonal methods, ADAM is a non-hormonal, reversible hydrogel injected into the vasa deferentia—the tubes that transport sperm from the testicles. The gel blocks sperm while still allowing for normal ejaculation, aiming to offer men long-term control over their fertility without permanent procedures.
Contraline reports that two participants maintained azoospermia (no sperm in ejaculate) at the 24-month mark. Earlier data showed a 99.8% to 100% reduction in moving sperm just 30 days after implantation. The company plans to present further findings at the American Urological Association meeting.
“Our goal was to create a male contraceptive lasting two years, and these results affirm we’ve achieved that,” said Dr. Alexander Pastuszak, Contraline’s Chief Medical Officer. CEO Kevin Eisenfrats added that ADAM could rival the efficacy of female IUDs and become a “no-brainer” option for men.
No serious side effects have been reported, and the trial is now approved to enter its second phase. Participants will continue to be monitored at multiple intervals for safety and reversibility.
Still, some experts caution that long-term effects and the implant’s reversibility remain unproven. But if proven successful, ADAM could finally shift the burden of birth control—offering men an active role in family planning for the long haul.
%20(1).jpg)
.png)
.png)
.png)